4//SEC Filing
Hoitt Jason 4
Accession 0001209191-19-040366
CIK 0001685071other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 4:55 PM ET
Size
7.3 KB
Accession
0001209191-19-040366
Insider Transaction Report
Form 4
Hoitt Jason
Chief Commercial Officer
Transactions
- Sale
Common Stock
2019-06-28$13.77/sh−2,237$30,803→ 20,087 total - Sale
Common Stock
2019-06-28$14.40/sh−150$2,160→ 19,937 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.35 to $14.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.38 to $14.43 inclusive.
Documents
Issuer
Dova Pharmaceuticals Inc.
CIK 0001685071
Entity typeother
Related Parties
1- filerCIK 0001762572
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 4:55 PM ET
- Size
- 7.3 KB